BofA upgraded Erasca to Neutral from Underperform with a price target of $16, up from $9. The firm says the investor debate is now shifting from whether ERAS-0015 works to whether it can matter commercially. The early pan-RAS activity \"appears real\" and key opinion leader feedback has been constructive, the analyst tells investors in a research note. BofA believes Erasca shares at current levels better reflect the known risks.
